文献リスト

1）Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004; 173: 55-68

2）Mabuchi H, Haba T, Tatami R, et al. Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. N Engl J Med. 1981; 305: 478-82

3）Mabuchi H, Kamon N, Fujita H, et al. Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia. Metabolism. 1987; 36: 475-9

4）Mol MJ, Erkelens DW, Leuven JA, et al. Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia. Lancet. 1986; 2: 936-9

5）Leclercq V, Harvengt C. Simvastatin (MK 733) in heterozygous familial hypercholesterolemia: a two-year trial. Int J Clin Pharmacol Ther Toxicol. 1989; 27: 76-81

6）Stalenhoef AF, Mol MJ, Stuyt PM. Efficacy and tolerability of simvastatin (MK-733). Am J Med. 1989; 87: 39S-43S

7）Leitersdorf E, Eisenberg S, Eliav O, et al. Efficacy and safety of high dose fluvastatin in patients with familial hypercholesterolaemia. Eur J Clin Pharmacol. 1993; 45: 513-8

8）Koizumi J, Haraki T, Yagi K, et al. Clinical efficacy of fluvastatin in the long-term treatment of familial hypercholesterolemia. Am J Cardiol. 1995; 76: 47A-50A

9）Wierzbicki AS, Lumb PJ, Semra YK, et al. High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia. QJM. 1998; 91: 291-4

10）Hoogerbrugge N. Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia. J Intern Med. 1998; 244: 143-7

11）Kajinami K, Koizumi J, Ueda K, et al. Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Hokuriku NK-104 Study Group. Am J Cardiol. 2000; 85: 178-83

12）Noji Y, Higashikata T, Inazu A, et al. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 2002; 163: 157-64

13）Ballantyne CM. Familial hypercholesterolaemia: optimum treatment strategies. Int J Clin Pract Suppl. 2002; 130: 22-6

14）Mabuchi H, Nohara A, Higashikata T, et al. Clinical efficacy and safety of rosuvastatin in Japanese patients with heterozygous familial hypercholesterolemia. J Atheroscler Thromb. 2004; 11: 152-8

15）寺本民生．スタチンの安全性評価と臨床的意義―米国NLAレポートより―．薬理と治療．2006; 34: 931-5

16）Stein E, Stender S, Mata P, et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J. 2004; 148: 447-55

17）Kosasayama A, Yoshida M, Okada S. Post-marketing surveillance of probucol (Sinlestal) in Japan. Artery. 1992; 19: 147-61

18）Anderson JL, Schroeder JS. Effects of probucol on hyperlipidemic patients with cardiac allografts. J Cardiovasc Pharmacol. 1979; 1: 353-65

19）Edison RJ, Muenke M. Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med. 2004; 350: 1579-82

20）Naito C, Yamamoto A, Saito Y, et al. Long term effect of LDL apheresis in Japan. LDL Apheresis Study Group. Biomater Artif Cells Immobilization Biotechnol. 1991; 19: 19-26

21）Koga N, Iwata Y, Yamamoto A. Angiographic and pathological studies on regression of coronary atherosclerosis of FH patients who received LDL-apheresis treatment. Artif Organs. 1992; 16: 171-6

22）Tatami R, Inoue N, Itoh H, et al. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. The LARS Investigators. Atherosclerosis. 1992; 95: 1-13

23）Takahashi T, Nakano S, Shimazaki Y, et al. Long-term appraisal of coronary bypass operations in familial hypercholesterolemia. Ann Thorac Surg. 1993; 56: 499-505

24）Yamamoto A, Harada-Shiba M, Kawaguchi A, et al. Apheresis technology for prevention and regression of atherosclerosis. Ther Apher. 2001; 5: 221-5

25）Tasaki H, Yamashita K, Saito Y, et al. Low-density lipoprotein apheresis therapy with a direct hemoperfusion column: a Japanese multicenter clinical trial. Ther Apher Dial. 2006; 10: 32-41

26）Mabuchi H, Koizumi J, Shimizu M, et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol. 1998; 82: 1489-95

27）Nishimura S, Sekiguchi M, Kano T, et al. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Atherosclerosis. 1999; 144: 409-17

28）Matsuzaki M, Hiramori K, Imaizumi T, et al. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). J Am Coll Cardiol. 2002; 40: 220-7

29）Kroon AA, Aengevaeren WR, van der Werf T, et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation. 1996; 93: 1826-35

30）Levy RI, Fredrickson DS, Stone NJ, et al. Cholestyramine in type II hyperlipoproteinemia. A double-blind trial. Ann Intern Med. 1973; 79: 51-8

31）Uauy R, Vega GL, Grundy SM, et al. Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentrations or turnover. J Pediatr. 1988; 113: 387-92

32）Malloy MJ, Kane JP, Kunitake ST, et al. Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia. Ann Intern Med. 1987; 107: 616-23

33）Yamamoto A, Harada-Shiba M, Kawaguchi A, et al. The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy. Atherosclerosis. 2000; 153: 89-98

34）Yamamoto A, Matsuzawa Y, Kishino B, et al. Effects of probucol on homozygous cases of familial hypercholesterolemia. Atherosclerosis. 1983; 48: 157-66

35）Baker SG, Joffe BI, Mendelsohn D, et al. Treatment of homozygous familial hypercholesterolaemia with probucol. S Afr Med J. 1982; 62: 7-11

36）Jones DB, Simpson HC, Slaughter P, et al. A comparison of cholestyramine and probucol in the treatment of familial hypercholesterolaemia. Atherosclerosis. 1984; 53: 1-7

37）Buckley MM, Goa KL, Price AH, et al. Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. Drugs. 1989; 37: 761-800

38）Yamamoto A, Harada-Shiba M, Endo M, et al. The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy. Atherosclerosis. 2006; 186: 126-31

39）Stefanutti C, Di Giacomo S, Vivenzio A, et al. Low-density lipoprotein apheresis in a patient aged 3.5 years. Acta Paediatr. 2001; 90: 694-701

40）Makino H, Harada-Shiba M. Long-term effect of low-density lipoprotein apheresis in patients with homozygous familial hypercholesterolemia. Ther Apher Dial. 2003; 7: 397-401

41）de Gennes JL, Touraine R, Maunand B, et al. [Homozygous cutaneo-tendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case. Trial of plasmapheresis ans heroic treatment]. Bull Mem Soc Med Hop Paris. 1967; 118: 1377-402

42）Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet. 1975; 1: 1208-11

43）Thompson GR, Myant NB, Kilpatrick D, et al. Assessment of long-term plasma exchange for familial hypercholesterolaemia. Br Heart J. 1980; 43: 680-8

44）Stein EA, Adolph R, Rice V, et al. Nonprogression of coronary artery atherosclerosis in homozygous familial hypercholesterolemia after 31 months of repetitive plasma exchange. Clin Cardiol. 1986; 9: 115-9

45）Berger GM, Miller JL, Bonnici F, et al. Continuous flow plasma exchange in the treatment of homozygous familial hypercholesterolemia. Am J Med. 1978; 65: 243-51

46）Graisely B, Cloarec M, Salmon S, et al. Extracorporeal plasma therapy for homozygous familial hypercholesterolaemia. Lancet. 1980; 2: 1147

47）King ME, Breslow JL, Lees RS. Plasma-exchange therapy of homozygous familial hypercholesterolemia. N Engl J Med. 1980; 302: 1457-9

48）Mimori A, Takahashi K, Mitamura T, et al. Clinical evaluation of three types of plasmapheresis in a patient with type IIa familial hypercholesterolemia. J Clin Apher. 1987; 3: 209-15

49）Yamamoto A, Yokoyama S, Satani M, et al. Evaluation of selective LDL-removal in the treatment of familial hypercholesterolemia: double membrane filtration and adsorption system. Prog Clin Biol Res. 1988; 255: 357-66

50）Suzuki M, Yamane S, Matsugane T, et al. Evaluation of double filtration plasmapheresis, thermofiltration, and low-density lipoprotein adsorptive methods by crossover test in the treatment of familial hypercholesterolemia patients. Artif Organs. 1996; 20: 296-302

51）Mabuchi H, Michishita I, Sakai T, et al. Treatment of homozygous patients with familial hypercholesterolemia by double-filtration plasmapheresis. Atherosclerosis. 1986; 61: 135-40

52）Leitman SF, Smith JW, Gregg RE. Homozygous familial hypercholesterolemia. Selective removal of low-density lipoproteins by secondary membrane filtration. Transfusion. 1989; 29: 341-6

53）Thompson GR. Plasma exchange for hypercholesterolaemia. Lancet. 1981; 1: 1246-8

54）Yokoyama S, Hayashi R, Kikkawa T, et al. Specific sorbent of apolipoprotein B-containing lipoproteins for plasmapheresis. Characterization and experimental use in hypercholesterolemic rabbits. Arteriosclerosis. 1984; 4: 276-82

55）Yokoyama S, Hayashi R, Satani M, et al. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis. 1985; 5: 613-22

56）Kojima S, Harada-Shiba M, Yamamoto A. Plasma constituents other than low-density lipoprotein adsorbed by dextran-sulfate column. Ther Apher. 1997; 1: 309-13

57）Bambauer R, Olbricht CJ, Schoeppe E. Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: clinical results. Ther Apher. 1997; 1: 242-8

58）Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012; 380: 1995-2006

59）Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012; 380: 2007-17

60）Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012; 308: 2497-506

61）Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012; 126: 2408-17

62）Yamamoto T, Harada-Shiba M, Nakatani M, et al. Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice. Mol Ther Nucleic Acids. 2012; 1: e22

63）Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010; 375: 998-1006

64）Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol. 2010; 105: 1413-9

65）Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012; 126: 2283-92

66）Akdim F, Stroes ES, Sijbrands EJ, et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol. 2010; 55: 1611-8

67）Thomas GS, Cromwell WC, Ali S, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2013; 62: 2178-84

68）Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2012; 33: 1142-9

69）Samaha FF, McKenney J, Bloedon LT, et al. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2008; 5: 497-505

70）Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007; 356: 148-56

71）Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013; 381: 40-6

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp